MNKD Q2 2024 Earnings — MannKind Corporation Revenue & Financial Results | Market Cap Arena

MNKDMannKind Corporation

$813M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$72M+48.9% YoY

Gross Profit

$52M71.8% margin

Operating Income

$17M22.9% margin

Net Income

-$2M-2.8% margin

EPS (Diluted)

$-0.01

QoQ Revenue Growth

+9.2%

Cash Flow

Operating Cash Flow

$4M

Free Cash Flow

$861,000

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$444M

Total Liabilities

$670M

Stockholders' Equity

-$226M

Cash & Equivalents

$97M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$72M	$49M	+48.9%
Gross Profit	$52M	$34M	+51.3%
Operating Income	$17M	$2M	+865.1%
Net Income	-$2M	-$5M	+61.7%

Revenue Segments

License And Service

$26M36%

Royalty

$26M35%

Product

$21M29%